Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DONALD C EAGERTON

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1609872498
CMS profile
163045
Location
MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29,885.89

135 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DONALD C EAGERTON

NPI 1609872498 · CMS profile ID 163045

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609872498?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DONALD C EAGERTON, NPI 1609872498, CMS profile ID 163045. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609872498?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DONALD C EAGERTON, NPI 1609872498, CMS profile ID 163045. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609872498?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DONALD C EAGERTON, NPI 1609872498, CMS profile ID 163045, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1609872498?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

135 matching records · $29,885.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 135 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–135 of 135.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $11.6103/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815201481 CMS
SANOFI-AVENTIS U.S. LLC $1,292.0003/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446887 CMS
Amarin Pharma Inc. $18.4403/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815041981 CMS
Antares Pharma, Inc. $11.6403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827514021 CMS
Abbott Laboratories $15.5403/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818434635 CMS
Janssen Biotech, Inc. $9.4003/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480153 CMS
Janssen Pharmaceuticals, Inc $11.8603/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480183 CMS
SANOFI-AVENTIS U.S. LLC $1,292.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446885 CMS
Eisai Inc. $14.6703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817848437 CMS
Amgen Inc. $14.9903/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825279065 CMS
Amgen Inc. $20.9302/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825279093 CMS
Radius Health, Inc. $15.6102/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830740005 CMS
Lilly USA, LLC $17.5702/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819073127 CMS
MannKind Corporation $17.3602/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821054645 CMS
MannKind Corporation $17.3602/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821054649 CMS
SANOFI-AVENTIS U.S. LLC $1,476.0002/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446901 CMS
Janssen Biotech, Inc. $16.9002/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480137 CMS
Novo Nordisk Inc $1,350.0002/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811213051 CMS
UCB, Inc. $15.4902/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807306223 CMS
Novo Nordisk Inc $1,350.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810830253 CMS
Novo Nordisk Inc $1,606.5002/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810830247 CMS
SANOFI-AVENTIS U.S. LLC $1,107.0002/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446879 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.4802/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917635 CMS
Amarin Pharma Inc. $20.2602/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815201477 CMS
Currax Pharmaceuticals LLC $12.3502/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792528383 CMS
SANOFI-AVENTIS U.S. LLC $1,107.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446873 CMS
Antares Pharma, Inc. $18.8902/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827477021 CMS
Janssen Biotech, Inc. $11.4502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480171 CMS
Janssen Pharmaceuticals, Inc $11.8602/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480173 CMS
SANOFI-AVENTIS U.S. LLC $17.3501/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843446883 CMS
Lilly USA, LLC $650.0001/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819155481 CMS
Janssen Biotech, Inc. $17.3001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788480131 CMS
Antares Pharma, Inc. $12.5401/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827514023 CMS
DEXCOM, INC. $13.3901/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845275821 CMS
AstraZeneca Pharmaceuticals LP $122.2901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829585131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $52,979.00 224
PY2020 $23,812.73 132
PY2021 $29,885.89 135
PY2022 $61,456.61 184
PY2023 $39,455.39 217
PY2024 $30,756.02 233
PY2025 $45,944.88 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,216,517.54 142
PY2024 Recipient $1,160.00 1
PY2024 Principal investigator $2,466,330.31 223
PY2023 Recipient $1,709.42 2
PY2023 Principal investigator $2,566,756.85 1,766
PY2022 Principal investigator $1,174,461.98 1,842
PY2021 Principal investigator $31,931.16 188
PY2020 Principal investigator $69,192.96 114
PY2019 Principal investigator $79,506.68 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723490
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 12/17/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723492
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 12/17/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723494
Principal investigator 1 ModernaTX, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975795
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723486
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723488
Principal investigator 1 ModernaTX, Inc. $7,517.61 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975813
Principal investigator 1 ModernaTX, Inc. $1,659.32 11/12/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006837
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $190.00 11/10/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220812004
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,768.90 11/05/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220812002
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723484
Principal investigator 1 ModernaTX, Inc. $2,383.55 10/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975767
Principal investigator 1 ModernaTX, Inc. $34,236.10 10/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975791
Principal investigator 1 ModernaTX, Inc. $22,598.60 10/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975819
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723478
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723480
Principal investigator 1 ModernaTX, Inc. $1,850.60 09/29/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975769
Principal investigator 1 ModernaTX, Inc. $1,189.40 09/29/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975789
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723476
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $600.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811982
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,875.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811984
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811986
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $194.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811988
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $194.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811990
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811992
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $263.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811994
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $194.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811996
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 09/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811998
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,147.20 09/03/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220812000
Principal investigator 1 ModernaTX, Inc. $7,956.00 09/03/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006803
Principal investigator 1 ModernaTX, Inc. $46.79 09/03/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006823
Principal investigator 1 ModernaTX, Inc. $1,304.12 09/03/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723458
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723468
Principal investigator 1 ModernaTX, Inc. $1,674.64 08/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006825
Principal investigator 1 ModernaTX, Inc. $494.00 08/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006831
Principal investigator 1 ModernaTX, Inc. $1,250.00 08/22/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975771
Principal investigator 1 ModernaTX, Inc. $325.00 08/22/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975773
Principal investigator 1 ModernaTX, Inc. $1,200.00 08/22/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975793
Principal investigator 1 ModernaTX, Inc. $5,450.00 08/22/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975821
Principal investigator 1 ModernaTX, Inc. $500.00 08/06/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006807
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723466
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723470
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723472
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 07/28/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723474
Principal investigator 1 ModernaTX, Inc. $6,000.00 07/16/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975803
Principal investigator 1 ModernaTX, Inc. $69,122.95 07/16/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975807
Principal investigator 1 ModernaTX, Inc. $303.75 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975775
Principal investigator 1 ModernaTX, Inc. $200.00 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975777
Principal investigator 1 ModernaTX, Inc. $106.65 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975779
Principal investigator 1 ModernaTX, Inc. $101.25 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975781
Principal investigator 1 ModernaTX, Inc. $67.50 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975797
Principal investigator 1 ModernaTX, Inc. $93.96 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975811
Principal investigator 1 ModernaTX, Inc. $94.50 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975823
Principal investigator 1 ModernaTX, Inc. $87.75 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252975825
Principal investigator 1 ModernaTX, Inc. $652.06 07/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006855
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 07/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723460
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723462
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723464
Principal investigator 1 Eli Lilly and Company $106,049.30 07/01/2025 Non-covered Recipient Entity
WRIGHTSVILLE FAMILY PRACTICE
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 No dispute reported 06/30/2026 1187892886
Principal investigator 1 PFIZER INC. $525.00 07/01/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228720417
Principal investigator 1 ModernaTX, Inc. $418.66 06/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006817
Principal investigator 1 Boehringer Ingelheim International GmbH $221.10 06/24/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723456
Principal investigator 1 ModernaTX, Inc. $66,566.94 06/18/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006857
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,376.90 06/12/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811980
Principal investigator 1 ModernaTX, Inc. $24,648.29 06/06/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975783
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723452
Principal investigator 1 ModernaTX, Inc. $37,012.00 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975763
Principal investigator 1 ModernaTX, Inc. $23,835.50 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975809
Principal investigator 1 ModernaTX, Inc. $1,200.00 05/28/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975831
Principal investigator 1 ModernaTX, Inc. $7,098.15 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006797
Principal investigator 1 ModernaTX, Inc. $33,911.46 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006841
Principal investigator 1 ModernaTX, Inc. $20,589.92 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006845
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723454
Principal investigator 1 ModernaTX, Inc. $500.00 05/16/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975799
Principal investigator 1 ModernaTX, Inc. $43.60 05/16/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975827
Principal investigator 1 ModernaTX, Inc. $5,002.22 05/16/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975829
Principal investigator 1 ModernaTX, Inc. $4,977.96 05/15/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006819
Principal investigator 1 ModernaTX, Inc. $1,155.05 05/15/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 05/12/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220807515
Principal investigator 1 PFIZER INC. $35,350.42 05/06/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228763263
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,717.00 05/05/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811978
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723446
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723448
Principal investigator 1 ModernaTX, Inc. $25,553.34 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006799
Principal investigator 1 ModernaTX, Inc. $1,419.63 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006811
Principal investigator 1 ModernaTX, Inc. $36,842.08 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006813
Principal investigator 1 ModernaTX, Inc. $418.66 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006827
Principal investigator 1 ModernaTX, Inc. $553.28 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006839
Principal investigator 1 ModernaTX, Inc. $41,654.08 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006853
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,905.45 04/11/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811976
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723442
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723444
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,862.96 03/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811974
Principal investigator 1 ModernaTX, Inc. $14,196.30 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006809
Principal investigator 1 ModernaTX, Inc. $8,330.70 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006815
Principal investigator 1 ModernaTX, Inc. $30,035.20 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006859
Principal investigator 1 ModernaTX, Inc. $22,188.98 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006861
Principal investigator 1 ModernaTX, Inc. $1,100.00 03/19/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252975785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723428
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723430
Principal investigator 1 ModernaTX, Inc. $104.00 02/28/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES, LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975765
Principal investigator 1 ModernaTX, Inc. $2,067.40 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006805
Principal investigator 1 ModernaTX, Inc. $38,330.01 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006821
Principal investigator 1 ModernaTX, Inc. $34,224.32 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006835
Principal investigator 1 ModernaTX, Inc. $57,356.42 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006867
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 02/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723432
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723434
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 02/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723436
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 02/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723438
Principal investigator 1 ModernaTX, Inc. $67.50 02/24/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults No dispute reported 06/30/2026 1252975787
Principal investigator 1 ModernaTX, Inc. $243.00 02/24/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults No dispute reported 06/30/2026 1252975801
Principal investigator 1 ModernaTX, Inc. $303.75 02/24/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults No dispute reported 06/30/2026 1252975815
Principal investigator 1 ModernaTX, Inc. $71.55 02/24/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults No dispute reported 06/30/2026 1252975817
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,188.45 02/20/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811972
Principal investigator 1 ModernaTX, Inc. $83.20 02/20/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES, LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252975805
Principal investigator 1 ModernaTX, Inc. $6,000.00 02/05/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006801
Principal investigator 1 ModernaTX, Inc. $1,000.00 02/05/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006843
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/05/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006849
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/05/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006865
Principal investigator 1 PFIZER INC. $1,794.00 02/05/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228749078
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723422
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723424
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723426
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,434.00 02/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220811970
Principal investigator 1 Eli Lilly and Company $694.93 01/31/2025 Non-covered Recipient Entity
WRIGHTSVILLE FAMILY PRACTICE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187891396
Principal investigator 1 Eli Lilly and Company $941.73 01/31/2025 Non-covered Recipient Entity
WRIGHTSVILLE FAMILY PRACTICE
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187893656
Principal investigator 1 Amgen Inc. $45,427.26 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246649936
Principal investigator 1 ModernaTX, Inc. $3,940.88 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006795
Principal investigator 1 ModernaTX, Inc. $1,698.74 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006833
Principal investigator 1 ModernaTX, Inc. $20,674.00 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006847
Principal investigator 1 ModernaTX, Inc. $11,107.60 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006863
Principal investigator 1 ModernaTX, Inc. $14,196.30 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006869
Principal investigator 1 ModernaTX, Inc. $21,182.72 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006871
Principal investigator 1 Eli Lilly and Company $75,185.00 01/21/2025 Non-covered Recipient Entity
WRIGHTSVILLE FAMILY PRACTICE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187892884
Principal investigator 1 PFIZER INC. $223.56 01/15/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798827
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,654.14 01/07/2025 Non-covered Recipient Entity
Trial Management Associates LLC
phase III efficacy for obesity - with T2DM No dispute reported 06/30/2026 1220812006
Principal investigator 1 Eli Lilly and Company $94,245.00 01/07/2025 Non-covered Recipient Entity
WRIGHTSVILLE FAMILY PRACTICE
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187893810
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723420
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220723440